NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Also pertinent is this:

As a reminder, the previous Phase II trial of DCVax-L is an ongoing randomized, placebo controlled, double blinded (2:1) study with a cross-over arm allowing control patients to be treated with DCVax-L in the event that their cancer progresses. The primary end point is progression free survival (PFS) with overall survival (:OS) as the secondary end point. The original 240-patient trial is designed to enable the Company to petition the FDA for accelerated approval if the study generates results similar to those achieved in the two prior Phase I clinical trials.